# OV01 Preference Label 2 - Transcript A vs B (workspace backup)

Stage: Step 15 Preference Labeling (Healthcare_297_Vasquell - Task 1, batch 20260615_082222).
Current status: DRAFT for read-and-own. No platform entry without Alexander's authorization for that exact step.

Studio-selected pair:
- Transcript A = 0.900, 15 steps, 11m 34s. Same 0.900 trajectory used in PL1.
- Transcript B = 0.850, 19 steps, 5m 49s. A different, stronger trajectory than PL1's B (0.720).
- Bundle IDs not shown in the pasted transcript; record from the download icons on submit.

Basis: both deliverable summaries read against `golden-OV01-v1.docx` and `grader-guidelines-OV01.txt`. The central capped failure for OV01 is continuing the carried-forward inpatient enoxaparin VTE prophylaxis at discharge (or carrying admission antibiotic dosing forward, or silently resuming or discontinuing a held agent). A 0.90 and B 0.85 are both high passes just under the 0.93 catcher, so this is a close both-pass pair (0.05 gap), decided against the central item with the conservative-margin calibration the skill requires.

KEY FINDING: A is better, narrowly. Both are thorough, chart-anchored reconciliations that get the surrounding Section A items right: both stop the carried-forward IV piperacillin-tazobactam (B additionally flags that cefepime and vancomycin need an explicit stop or transition), both hold metformin, empagliflozin, and lisinopril with reasons, both retain acetaminophen with no NSAID, both continue home insulin, and both add back the two dropped home medications (ferrous sulfate and cholecalciferol). Neither discontinues the carried-forward inpatient-only enoxaparin, the central designed item. The difference on that item is narrow: B states the correct underlying principle more explicitly, that enoxaparin is prophylaxis and not a home medication, but its verdict is "Sign with conditions" and it calls the rationale "sound," which endorses conditional continuation; A does not name the principle but reaches a marginally more cautious verdict, "CHANGE, confirm it is still indicated at discharge, with a defined stop criterion." Both still describe the injection in the patient instructions, so that part is a shared miss, not a differentiator. Since the central failure is continuing the prophylaxis, A's less-endorsing verdict is the marginally safer of two partial handlings. The margin is plain A (no plus), narrower than PL1, because B here makes no discrete factual error (contrast PL1's provenance mislabel) and actually articulates the inpatient-only principle to its credit.

VERDICT: A1 (A slightly better). Button = plain A (no plus sign).

## Justification

Preferred output: A

Justification: The central failure for OV01 is continuing the carried-forward inpatient enoxaparin VTE prophylaxis at discharge. Neither output discontinues it, so both give a partial handling and the pair is decided on which partial handling is marginally less wrong. B articulates the correct underlying principle, that enoxaparin is prophylaxis and not a home medication, more explicitly than A, but B's verdict is "Sign with conditions," it calls the rationale "sound," and it endorses signing the inpatient-only agent if she goes home. A does not name the principle but reaches a marginally more cautious verdict, "CHANGE, confirm it is still indicated at discharge, with a defined stop criterion," which leans away from continuation. Because the designed failure is continuation, A's verdict is the marginally safer of the two. The margin is plain A, not A+, because neither discontinues the agent and B makes no discrete factual error here.

Prompt adherence: Both go line by line over all fourteen orders, write plain-language patient instructions, and flag confirm-before-sign items. Both answer the requested workflow. Tie on basic prompt adherence.

Correctness: Both are correct on the surrounding Section A items: stop the carried-forward IV piperacillin-tazobactam, hold metformin and empagliflozin and defer lisinopril with reasons, retain acetaminophen with no NSAID, continue home insulin, treat the antibiotic as non-culture-directed requiring deep-culture-directed de-escalation, and exclude TMP-SMX for the sulfa allergy. On the central item, neither discontinues enoxaparin. B correctly identifies it as prophylaxis and not a home medication, which is the golden's reasoning, but then endorses signing it with conditions; A questions whether it is still indicated and asks for a stop criterion. Their net correctness on the central item is close, with A marginally less endorsing of continuation. B is marginally more explicit on the antibiotic clean-up, naming an explicit stop or transition for cefepime and vancomycin.

Completeness: Both are highly complete. Both surface the unfinalized disposition prominently, both catch the two dropped home medications with the anemia context, and both specify the insulin numbers and scale needed before sign. B adds the explicit cefepime and vancomycin stop or transition and the glucometer supplies; A adds the explicit triple-antithrombotic bleeding framing. Roughly even, each slightly more complete on a different secondary point.

Methodology: Both read the full chart, reconcile against the MAR and the held-order set, and check the renal trend and the imaging against the reports. Both correctly read the carried-forward status of the order set. The methods are equivalent; the small difference is interpretive, B endorsing conditional continuation of the prophylaxis while A questions its indication.

Quality and clarity: Both are organized, chart-anchored, and sign-ready, with clear verdict columns and a confirm-before-sign list. Quality is comparable. The grader directs not to weight formatting, so this dimension is neutral.

Summary: A is preferred at plain A by a narrow margin. The decider is the central enoxaparin item, which neither discontinues. B states the correct inpatient-only principle more explicitly but endorses signing the prophylaxis with conditions, while A reaches a marginally more cautious verdict that questions the indication and asks for a stop criterion. Because the designed failure is continuation, A's less-endorsing verdict is marginally safer. The margin is plain A, not A+, because neither discontinues the agent and B makes no discrete factual error here, unlike the provenance mislabel that decided PL1.

## Guardrails (must survive any edit)
1. Preferred output is A. Button = plain A (no plus sign).
2. The decider is the central enoxaparin item. Neither discontinues it. A's "CHANGE, confirm still indicated, stop criterion" is marginally less endorsing of continuation than B's "Sign with conditions, rationale is sound." Do not recharacterize A as a clean catch.
3. Margin is plain A (A1), narrower than PL1's A+. Reasons: the grader gap is 0.05, B makes no discrete factual error here, and B actually articulates the inpatient-only "not a home med" principle. Do not inflate to A+.
4. Do not penalize B for the "not a home med" insight; it is correct and to its credit. B's weakness is only that it still endorses conditional signing rather than discontinuation.
5. Both are correct on the surrounding Section A items (stop pip-tazo, hold the three oral agents, no NSAID, continue insulin, deep-culture-directed renally dosed antibiotic, add back ferrous sulfate and cholecalciferol). Do not treat those as differentiators; B is marginally more explicit on stopping cefepime and vancomycin.
6. Transcript A is the same 0.900 trajectory used in PL1; Transcript B here (0.850) is a different, stronger trajectory than PL1's B (0.720). PL 2 of 3 for OV01.

## Submit mechanics
Select plain A (no plus sign), paste the justification from "Preferred output: A" through the Summary into Comments, submit the preference, confirm it appears in submission history, then run Preference Labels AutoQC. Do not submit until Alexander authorizes this exact step.
